 | • レポートコード：MRC2-11QY01142 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、111ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は遺伝性血管性浮腫薬のグローバル市場について調査・分析したレポートです。種類別（C1エステラーゼ阻害剤、カリクレイン阻害剤、選択的ブラジキニンB2受容体拮抗薬）市場規模、用途別（小売薬局、病院薬局、オンライン薬局）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別遺伝性血管性浮腫薬の競争状況、市場シェア ・世界の遺伝性血管性浮腫薬市場：種類別市場規模 2015年-2020年（C1エステラーゼ阻害剤、カリクレイン阻害剤、選択的ブラジキニンB2受容体拮抗薬） ・世界の遺伝性血管性浮腫薬市場：種類別市場規模予測 2021年-2026年（C1エステラーゼ阻害剤、カリクレイン阻害剤、選択的ブラジキニンB2受容体拮抗薬） ・世界の遺伝性血管性浮腫薬市場：用途別市場規模 2015年-2020年（小売薬局、病院薬局、オンライン薬局） ・世界の遺伝性血管性浮腫薬市場：用途別市場規模予測 2021年-2026年（小売薬局、病院薬局、オンライン薬局） ・北米の遺伝性血管性浮腫薬市場分析：米国、カナダ ・ヨーロッパの遺伝性血管性浮腫薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの遺伝性血管性浮腫薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の遺伝性血管性浮腫薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの遺伝性血管性浮腫薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Pharming Group NV、Takeda、CSL Limited、IBio Inc.、BioCryst Pharmaceuticals, Inc.、Ionis Pharmaceuticals, Inc. ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
In the past 2 years, the FDA has approved 3 new drugs for prevention or treatment of hereditary angioedema (HAE) in non-pregnant adolescents and adults: the C1 esterase inhibitor Cinryze for prophylaxis and the C1 esterase inhibitor Berinert and the kallikrein inhibitor ecallantide (Kalbitor) for treatment of acute attacks.
Market Analysis and Insights: Global Hereditary Angioedema Drug Market
The global Hereditary Angioedema Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Hereditary Angioedema Drug Scope and Market Size
Hereditary Angioedema Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Hereditary Angioedema Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Hereditary Angioedema Drug market is segmented into
C1 Esterase Inhibitor
Kallikrein Inhibitor
Selective Bradykinin B2 Receptor Antagonist
Segment by Application, the Hereditary Angioedema Drug market is segmented into
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Regional and Country-level Analysis
The Hereditary Angioedema Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the Hereditary Angioedema Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Hereditary Angioedema Drug Market Share Analysis
Hereditary Angioedema Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Hereditary Angioedema Drug business, the date to enter into the Hereditary Angioedema Drug market, Hereditary Angioedema Drug product introduction, recent developments, etc.
The major vendors covered:
Pharming Group NV
Takeda
CSL Limited
IBio Inc.
BioCryst Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
…
1 Study Coverage
1.1 Hereditary Angioedema Drug Product Introduction
1.2 Market Segments
1.3 Key Hereditary Angioedema Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Hereditary Angioedema Drug Market Size Growth Rate by Type
1.4.2 C1 Esterase Inhibitor
1.4.3 Kallikrein Inhibitor
1.4.4 Selective Bradykinin B2 Receptor Antagonist
1.5 Market by Application
1.5.1 Global Hereditary Angioedema Drug Market Size Growth Rate by Application
1.5.2 Retail Pharmacies
1.5.3 Hospital Pharmacies
1.5.4 Online Pharmacies
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Hereditary Angioedema Drug Market Size, Estimates and Forecasts
2.1.1 Global Hereditary Angioedema Drug Revenue 2015-2026
2.1.2 Global Hereditary Angioedema Drug Sales 2015-2026
2.2 Global Hereditary Angioedema Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Hereditary Angioedema Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Hereditary Angioedema Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Hereditary Angioedema Drug Competitor Landscape by Players
3.1 Hereditary Angioedema Drug Sales by Manufacturers
3.1.1 Hereditary Angioedema Drug Sales by Manufacturers (2015-2020)
3.1.2 Hereditary Angioedema Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Hereditary Angioedema Drug Revenue by Manufacturers
3.2.1 Hereditary Angioedema Drug Revenue by Manufacturers (2015-2020)
3.2.2 Hereditary Angioedema Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Hereditary Angioedema Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Hereditary Angioedema Drug Revenue in 2019
3.2.5 Global Hereditary Angioedema Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Hereditary Angioedema Drug Price by Manufacturers
3.4 Hereditary Angioedema Drug Manufacturing Base Distribution, Product Types
3.4.1 Hereditary Angioedema Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Hereditary Angioedema Drug Product Type
3.4.3 Date of International Manufacturers Enter into Hereditary Angioedema Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Hereditary Angioedema Drug Market Size by Type (2015-2020)
4.1.1 Global Hereditary Angioedema Drug Sales by Type (2015-2020)
4.1.2 Global Hereditary Angioedema Drug Revenue by Type (2015-2020)
4.1.3 Hereditary Angioedema Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Hereditary Angioedema Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Hereditary Angioedema Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Hereditary Angioedema Drug Revenue Forecast by Type (2021-2026)
4.2.3 Hereditary Angioedema Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Hereditary Angioedema Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Hereditary Angioedema Drug Market Size by Application (2015-2020)
5.1.1 Global Hereditary Angioedema Drug Sales by Application (2015-2020)
5.1.2 Global Hereditary Angioedema Drug Revenue by Application (2015-2020)
5.1.3 Hereditary Angioedema Drug Price by Application (2015-2020)
5.2 Hereditary Angioedema Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Hereditary Angioedema Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Hereditary Angioedema Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Hereditary Angioedema Drug Price Forecast by Application (2021-2026)
6 North America
6.1 North America Hereditary Angioedema Drug by Country
6.1.1 North America Hereditary Angioedema Drug Sales by Country
6.1.2 North America Hereditary Angioedema Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Hereditary Angioedema Drug Market Facts & Figures by Type
6.3 North America Hereditary Angioedema Drug Market Facts & Figures by Application
7 Europe
7.1 Europe Hereditary Angioedema Drug by Country
7.1.1 Europe Hereditary Angioedema Drug Sales by Country
7.1.2 Europe Hereditary Angioedema Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Hereditary Angioedema Drug Market Facts & Figures by Type
7.3 Europe Hereditary Angioedema Drug Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Hereditary Angioedema Drug by Region
8.1.1 Asia Pacific Hereditary Angioedema Drug Sales by Region
8.1.2 Asia Pacific Hereditary Angioedema Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Hereditary Angioedema Drug Market Facts & Figures by Type
8.3 Asia Pacific Hereditary Angioedema Drug Market Facts & Figures by Application
9 Latin America
9.1 Latin America Hereditary Angioedema Drug by Country
9.1.1 Latin America Hereditary Angioedema Drug Sales by Country
9.1.2 Latin America Hereditary Angioedema Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Hereditary Angioedema Drug Market Facts & Figures by Type
9.3 Central & South America Hereditary Angioedema Drug Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Hereditary Angioedema Drug by Country
10.1.1 Middle East and Africa Hereditary Angioedema Drug Sales by Country
10.1.2 Middle East and Africa Hereditary Angioedema Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Hereditary Angioedema Drug Market Facts & Figures by Type
10.3 Middle East and Africa Hereditary Angioedema Drug Market Facts & Figures by Application
11 Company Profiles
11.1 Pharming Group NV
11.1.1 Pharming Group NV Corporation Information
11.1.2 Pharming Group NV Description and Business Overview
11.1.3 Pharming Group NV Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Pharming Group NV Hereditary Angioedema Drug Products Offered
11.1.5 Pharming Group NV Related Developments
11.2 Takeda
11.2.1 Takeda Corporation Information
11.2.2 Takeda Description and Business Overview
11.2.3 Takeda Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Takeda Hereditary Angioedema Drug Products Offered
11.2.5 Takeda Related Developments
11.3 CSL Limited
11.3.1 CSL Limited Corporation Information
11.3.2 CSL Limited Description and Business Overview
11.3.3 CSL Limited Sales, Revenue and Gross Margin (2015-2020)
11.3.4 CSL Limited Hereditary Angioedema Drug Products Offered
11.3.5 CSL Limited Related Developments
11.4 IBio Inc.
11.4.1 IBio Inc. Corporation Information
11.4.2 IBio Inc. Description and Business Overview
11.4.3 IBio Inc. Sales, Revenue and Gross Margin (2015-2020)
11.4.4 IBio Inc. Hereditary Angioedema Drug Products Offered
11.4.5 IBio Inc. Related Developments
11.5 BioCryst Pharmaceuticals, Inc.
11.5.1 BioCryst Pharmaceuticals, Inc. Corporation Information
11.5.2 BioCryst Pharmaceuticals, Inc. Description and Business Overview
11.5.3 BioCryst Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.5.4 BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Products Offered
11.5.5 BioCryst Pharmaceuticals, Inc. Related Developments
11.6 Ionis Pharmaceuticals, Inc.
11.6.1 Ionis Pharmaceuticals, Inc. Corporation Information
11.6.2 Ionis Pharmaceuticals, Inc. Description and Business Overview
11.6.3 Ionis Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Products Offered
11.6.5 Ionis Pharmaceuticals, Inc. Related Developments
11.1 Pharming Group NV
11.1.1 Pharming Group NV Corporation Information
11.1.2 Pharming Group NV Description and Business Overview
11.1.3 Pharming Group NV Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Pharming Group NV Hereditary Angioedema Drug Products Offered
11.1.5 Pharming Group NV Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Hereditary Angioedema Drug Market Estimates and Projections by Region
12.1.1 Global Hereditary Angioedema Drug Sales Forecast by Regions 2021-2026
12.1.2 Global Hereditary Angioedema Drug Revenue Forecast by Regions 2021-2026
12.2 North America Hereditary Angioedema Drug Market Size Forecast (2021-2026)
12.2.1 North America: Hereditary Angioedema Drug Sales Forecast (2021-2026)
12.2.2 North America: Hereditary Angioedema Drug Revenue Forecast (2021-2026)
12.2.3 North America: Hereditary Angioedema Drug Market Size Forecast by Country (2021-2026)
12.3 Europe Hereditary Angioedema Drug Market Size Forecast (2021-2026)
12.3.1 Europe: Hereditary Angioedema Drug Sales Forecast (2021-2026)
12.3.2 Europe: Hereditary Angioedema Drug Revenue Forecast (2021-2026)
12.3.3 Europe: Hereditary Angioedema Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Hereditary Angioedema Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Hereditary Angioedema Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Hereditary Angioedema Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Hereditary Angioedema Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America Hereditary Angioedema Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: Hereditary Angioedema Drug Sales Forecast (2021-2026)
12.5.2 Latin America: Hereditary Angioedema Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: Hereditary Angioedema Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Hereditary Angioedema Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Hereditary Angioedema Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Hereditary Angioedema Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Hereditary Angioedema Drug Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Hereditary Angioedema Drug Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Hereditary Angioedema Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Hereditary Angioedema Drug Market Segments
Table 2. Ranking of Global Top Hereditary Angioedema Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Hereditary Angioedema Drug Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of C1 Esterase Inhibitor
Table 5. Major Manufacturers of Kallikrein Inhibitor
Table 6. Major Manufacturers of Selective Bradykinin B2 Receptor Antagonist
Table 7. Global Hereditary Angioedema Drug Market Size Growth Rate by Application 2020-2026 (K Units)
Table 8. Global Hereditary Angioedema Drug Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 9. Global Hereditary Angioedema Drug Sales by Regions 2015-2020 (K Units)
Table 10. Global Hereditary Angioedema Drug Sales Market Share by Regions (2015-2020)
Table 11. Global Hereditary Angioedema Drug Revenue by Regions 2015-2020 (US$ Million)
Table 12. Global Hereditary Angioedema Drug Sales by Manufacturers (2015-2020) (K Units)
Table 13. Global Hereditary Angioedema Drug Sales Share by Manufacturers (2015-2020)
Table 14. Global Hereditary Angioedema Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 15. Global Hereditary Angioedema Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hereditary Angioedema Drug as of 2019)
Table 16. Hereditary Angioedema Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 17. Hereditary Angioedema Drug Revenue Share by Manufacturers (2015-2020)
Table 18. Key Manufacturers Hereditary Angioedema Drug Price (2015-2020) (USD/Unit)
Table 19. Hereditary Angioedema Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 20. Manufacturers Hereditary Angioedema Drug Product Type
Table 21. Date of International Manufacturers Enter into Hereditary Angioedema Drug Market
Table 22. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 23. Global Hereditary Angioedema Drug Sales by Type (2015-2020) (K Units)
Table 24. Global Hereditary Angioedema Drug Sales Share by Type (2015-2020)
Table 25. Global Hereditary Angioedema Drug Revenue by Type (2015-2020) (US$ Million)
Table 26. Global Hereditary Angioedema Drug Revenue Share by Type (2015-2020)
Table 27. Hereditary Angioedema Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 28. Global Hereditary Angioedema Drug Sales by Application (2015-2020) (K Units)
Table 29. Global Hereditary Angioedema Drug Sales Share by Application (2015-2020)
Table 30. North America Hereditary Angioedema Drug Sales by Country (2015-2020) (K Units)
Table 31. North America Hereditary Angioedema Drug Sales Market Share by Country (2015-2020)
Table 32. North America Hereditary Angioedema Drug Revenue by Country (2015-2020) (US$ Million)
Table 33. North America Hereditary Angioedema Drug Revenue Market Share by Country (2015-2020)
Table 34. North America Hereditary Angioedema Drug Sales by Type (2015-2020) (K Units)
Table 35. North America Hereditary Angioedema Drug Sales Market Share by Type (2015-2020)
Table 36. North America Hereditary Angioedema Drug Sales by Application (2015-2020) (K Units)
Table 37. North America Hereditary Angioedema Drug Sales Market Share by Application (2015-2020)
Table 38. Europe Hereditary Angioedema Drug Sales by Country (2015-2020) (K Units)
Table 39. Europe Hereditary Angioedema Drug Sales Market Share by Country (2015-2020)
Table 40. Europe Hereditary Angioedema Drug Revenue by Country (2015-2020) (US$ Million)
Table 41. Europe Hereditary Angioedema Drug Revenue Market Share by Country (2015-2020)
Table 42. Europe Hereditary Angioedema Drug Sales by Type (2015-2020) (K Units)
Table 43. Europe Hereditary Angioedema Drug Sales Market Share by Type (2015-2020)
Table 44. Europe Hereditary Angioedema Drug Sales by Application (2015-2020) (K Units)
Table 45. Europe Hereditary Angioedema Drug Sales Market Share by Application (2015-2020)
Table 46. Asia Pacific Hereditary Angioedema Drug Sales by Region (2015-2020) (K Units)
Table 47. Asia Pacific Hereditary Angioedema Drug Sales Market Share by Region (2015-2020)
Table 48. Asia Pacific Hereditary Angioedema Drug Revenue by Region (2015-2020) (US$ Million)
Table 49. Asia Pacific Hereditary Angioedema Drug Revenue Market Share by Region (2015-2020)
Table 50. Asia Pacific Hereditary Angioedema Drug Sales by Type (2015-2020) (K Units)
Table 51. Asia Pacific Hereditary Angioedema Drug Sales Market Share by Type (2015-2020)
Table 52. Asia Pacific Hereditary Angioedema Drug Sales by Application (2015-2020) (K Units)
Table 53. Asia Pacific Hereditary Angioedema Drug Sales Market Share by Application (2015-2020)
Table 54. Latin America Hereditary Angioedema Drug Sales by Country (2015-2020) (K Units)
Table 55. Latin America Hereditary Angioedema Drug Sales Market Share by Country (2015-2020)
Table 56. Latin Americaa Hereditary Angioedema Drug Revenue by Country (2015-2020) (US$ Million)
Table 57. Latin America Hereditary Angioedema Drug Revenue Market Share by Country (2015-2020)
Table 58. Latin America Hereditary Angioedema Drug Sales by Type (2015-2020) (K Units)
Table 59. Latin America Hereditary Angioedema Drug Sales Market Share by Type (2015-2020)
Table 60. Latin America Hereditary Angioedema Drug Sales by Application (2015-2020) (K Units)
Table 61. Latin America Hereditary Angioedema Drug Sales Market Share by Application (2015-2020)
Table 62. Middle East and Africa Hereditary Angioedema Drug Sales by Country (2015-2020) (K Units)
Table 63. Middle East and Africa Hereditary Angioedema Drug Sales Market Share by Country (2015-2020)
Table 64. Middle East and Africa Hereditary Angioedema Drug Revenue by Country (2015-2020) (US$ Million)
Table 65. Middle East and Africa Hereditary Angioedema Drug Revenue Market Share by Country (2015-2020)
Table 66. Middle East and Africa Hereditary Angioedema Drug Sales by Type (2015-2020) (K Units)
Table 67. Middle East and Africa Hereditary Angioedema Drug Sales Market Share by Type (2015-2020)
Table 68. Middle East and Africa Hereditary Angioedema Drug Sales by Application (2015-2020) (K Units)
Table 69. Middle East and Africa Hereditary Angioedema Drug Sales Market Share by Application (2015-2020)
Table 70. Pharming Group NV Corporation Information
Table 71. Pharming Group NV Description and Major Businesses
Table 72. Pharming Group NV Hereditary Angioedema Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 73. Pharming Group NV Product
Table 74. Pharming Group NV Recent Development
Table 75. Takeda Corporation Information
Table 76. Takeda Description and Major Businesses
Table 77. Takeda Hereditary Angioedema Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 78. Takeda Product
Table 79. Takeda Recent Development
Table 80. CSL Limited Corporation Information
Table 81. CSL Limited Description and Major Businesses
Table 82. CSL Limited Hereditary Angioedema Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 83. CSL Limited Product
Table 84. CSL Limited Recent Development
Table 85. IBio Inc. Corporation Information
Table 86. IBio Inc. Description and Major Businesses
Table 87. IBio Inc. Hereditary Angioedema Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 88. IBio Inc. Product
Table 89. IBio Inc. Recent Development
Table 90. BioCryst Pharmaceuticals, Inc. Corporation Information
Table 91. BioCryst Pharmaceuticals, Inc. Description and Major Businesses
Table 92. BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 93. BioCryst Pharmaceuticals, Inc. Product
Table 94. BioCryst Pharmaceuticals, Inc. Recent Development
Table 95. Ionis Pharmaceuticals, Inc. Corporation Information
Table 96. Ionis Pharmaceuticals, Inc. Description and Major Businesses
Table 97. Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 98. Ionis Pharmaceuticals, Inc. Product
Table 99. Ionis Pharmaceuticals, Inc. Recent Development
Table 100. Global Hereditary Angioedema Drug Sales Forecast by Regions (2021-2026) (K Units)
Table 101. Global Hereditary Angioedema Drug Sales Market Share Forecast by Regions (2021-2026)
Table 102. Global Hereditary Angioedema Drug Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 103. Global Hereditary Angioedema Drug Revenue Market Share Forecast by Regions (2021-2026)
Table 104. North America: Hereditary Angioedema Drug Sales Forecast by Country (2021-2026) (K Units)
Table 105. North America: Hereditary Angioedema Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 106. Europe: Hereditary Angioedema Drug Sales Forecast by Country (2021-2026) (K Units)
Table 107. Europe: Hereditary Angioedema Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 108. Asia Pacific: Hereditary Angioedema Drug Sales Forecast by Region (2021-2026) (K Units)
Table 109. Asia Pacific: Hereditary Angioedema Drug Revenue Forecast by Region (2021-2026) (US$ Million)
Table 110. Latin America: Hereditary Angioedema Drug Sales Forecast by Country (2021-2026) (K Units)
Table 111. Latin America: Hereditary Angioedema Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 112. Middle East and Africa: Hereditary Angioedema Drug Sales Forecast by Country (2021-2026) (K Units)
Table 113. Middle East and Africa: Hereditary Angioedema Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 114. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 115. Key Challenges
Table 116. Market Risks
Table 117. Main Points Interviewed from Key Hereditary Angioedema Drug Players
Table 118. Hereditary Angioedema Drug Customers List
Table 119. Hereditary Angioedema Drug Distributors List
Table 120. Research Programs/Design for This Report
Table 121. Key Data Information from Secondary Sources
Table 122. Key Data Information from Primary Sources
List of Figures
Figure 1. Hereditary Angioedema Drug Product Picture
Figure 2. Global Hereditary Angioedema Drug Sales Market Share by Type in 2020 & 2026
Figure 3. C1 Esterase Inhibitor Product Picture
Figure 4. Kallikrein Inhibitor Product Picture
Figure 5. Selective Bradykinin B2 Receptor Antagonist Product Picture
Figure 6. Global Hereditary Angioedema Drug Sales Market Share by Application in 2020 & 2026
Figure 7. Retail Pharmacies
Figure 8. Hospital Pharmacies
Figure 9. Online Pharmacies
Figure 10. Hereditary Angioedema Drug Report Years Considered
Figure 11. Global Hereditary Angioedema Drug Market Size 2015-2026 (US$ Million)
Figure 12. Global Hereditary Angioedema Drug Sales 2015-2026 (K Units)
Figure 13. Global Hereditary Angioedema Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 14. Global Hereditary Angioedema Drug Sales Market Share by Region (2015-2020)
Figure 15. Global Hereditary Angioedema Drug Sales Market Share by Region in 2019
Figure 16. Global Hereditary Angioedema Drug Revenue Market Share by Region (2015-2020)
Figure 17. Global Hereditary Angioedema Drug Revenue Market Share by Region in 2019
Figure 18. Global Hereditary Angioedema Drug Sales Share by Manufacturer in 2019
Figure 19. The Top 10 and 5 Players Market Share by Hereditary Angioedema Drug Revenue in 2019
Figure 20. Hereditary Angioedema Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 21. Global Hereditary Angioedema Drug Sales Market Share by Type (2015-2020)
Figure 22. Global Hereditary Angioedema Drug Sales Market Share by Type in 2019
Figure 23. Global Hereditary Angioedema Drug Revenue Market Share by Type (2015-2020)
Figure 24. Global Hereditary Angioedema Drug Revenue Market Share by Type in 2019
Figure 25. Global Hereditary Angioedema Drug Market Share by Price Range (2015-2020)
Figure 26. Global Hereditary Angioedema Drug Sales Market Share by Application (2015-2020)
Figure 27. Global Hereditary Angioedema Drug Sales Market Share by Application in 2019
Figure 28. Global Hereditary Angioedema Drug Revenue Market Share by Application (2015-2020)
Figure 29. Global Hereditary Angioedema Drug Revenue Market Share by Application in 2019
Figure 30. North America Hereditary Angioedema Drug Sales Growth Rate 2015-2020 (K Units)
Figure 31. North America Hereditary Angioedema Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 32. North America Hereditary Angioedema Drug Sales Market Share by Country in 2019
Figure 33. North America Hereditary Angioedema Drug Revenue Market Share by Country in 2019
Figure 34. U.S. Hereditary Angioedema Drug Sales Growth Rate (2015-2020) (K Units)
Figure 35. U.S. Hereditary Angioedema Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 36. Canada Hereditary Angioedema Drug Sales Growth Rate (2015-2020) (K Units)
Figure 37. Canada Hereditary Angioedema Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. North America Hereditary Angioedema Drug Market Share by Type in 2019
Figure 39. North America Hereditary Angioedema Drug Market Share by Application in 2019
Figure 40. Europe Hereditary Angioedema Drug Sales Growth Rate 2015-2020 (K Units)
Figure 41. Europe Hereditary Angioedema Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 42. Europe Hereditary Angioedema Drug Sales Market Share by Country in 2019
Figure 43. Europe Hereditary Angioedema Drug Revenue Market Share by Country in 2019
Figure 44. Germany Hereditary Angioedema Drug Sales Growth Rate (2015-2020) (K Units)
Figure 45. Germany Hereditary Angioedema Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 46. France Hereditary Angioedema Drug Sales Growth Rate (2015-2020) (K Units)
Figure 47. France Hereditary Angioedema Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. U.K. Hereditary Angioedema Drug Sales Growth Rate (2015-2020) (K Units)
Figure 49. U.K. Hereditary Angioedema Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. Italy Hereditary Angioedema Drug Sales Growth Rate (2015-2020) (K Units)
Figure 51. Italy Hereditary Angioedema Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Russia Hereditary Angioedema Drug Sales Growth Rate (2015-2020) (K Units)
Figure 53. Russia Hereditary Angioedema Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Europe Hereditary Angioedema Drug Market Share by Type in 2019
Figure 55. Europe Hereditary Angioedema Drug Market Share by Application in 2019
Figure 56. Asia Pacific Hereditary Angioedema Drug Sales Growth Rate 2015-2020 (K Units)
Figure 57. Asia Pacific Hereditary Angioedema Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 58. Asia Pacific Hereditary Angioedema Drug Sales Market Share by Region in 2019
Figure 59. Asia Pacific Hereditary Angioedema Drug Revenue Market Share by Region in 2019
Figure 60. China Hereditary Angioedema Drug Sales Growth Rate (2015-2020) (K Units)
Figure 61. China Hereditary Angioedema Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 62. Japan Hereditary Angioedema Drug Sales Growth Rate (2015-2020) (K Units)
Figure 63. Japan Hereditary Angioedema Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. South Korea Hereditary Angioedema Drug Sales Growth Rate (2015-2020) (K Units)
Figure 65. South Korea Hereditary Angioedema Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. India Hereditary Angioedema Drug Sales Growth Rate (2015-2020) (K Units)
Figure 67. India Hereditary Angioedema Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. Australia Hereditary Angioedema Drug Sales Growth Rate (2015-2020) (K Units)
Figure 69. Australia Hereditary Angioedema Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Taiwan Hereditary Angioedema Drug Sales Growth Rate (2015-2020) (K Units)
Figure 71. Taiwan Hereditary Angioedema Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Indonesia Hereditary Angioedema Drug Sales Growth Rate (2015-2020) (K Units)
Figure 73. Indonesia Hereditary Angioedema Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Thailand Hereditary Angioedema Drug Sales Growth Rate (2015-2020) (K Units)
Figure 75. Thailand Hereditary Angioedema Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Malaysia Hereditary Angioedema Drug Sales Growth Rate (2015-2020) (K Units)
Figure 77. Malaysia Hereditary Angioedema Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Philippines Hereditary Angioedema Drug Sales Growth Rate (2015-2020) (K Units)
Figure 79. Philippines Hereditary Angioedema Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Vietnam Hereditary Angioedema Drug Sales Growth Rate (2015-2020) (K Units)
Figure 81. Vietnam Hereditary Angioedema Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Asia Pacific Hereditary Angioedema Drug Market Share by Type in 2019
Figure 83. Asia Pacific Hereditary Angioedema Drug Market Share by Application in 2019
Figure 84. Latin America Hereditary Angioedema Drug Sales Growth Rate 2015-2020 (K Units)
Figure 85. Latin America Hereditary Angioedema Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 86. Latin America Hereditary Angioedema Drug Sales Market Share by Country in 2019
Figure 87. Latin America Hereditary Angioedema Drug Revenue Market Share by Country in 2019
Figure 88. Mexico Hereditary Angioedema Drug Sales Growth Rate (2015-2020) (K Units)
Figure 89. Mexico Hereditary Angioedema Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 90. Brazil Hereditary Angioedema Drug Sales Growth Rate (2015-2020) (K Units)
Figure 91. Brazil Hereditary Angioedema Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Argentina Hereditary Angioedema Drug Sales Growth Rate (2015-2020) (K Units)
Figure 93. Argentina Hereditary Angioedema Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Latin America Hereditary Angioedema Drug Market Share by Type in 2019
Figure 95. Latin America Hereditary Angioedema Drug Market Share by Application in 2019
Figure 96. Middle East and Africa Hereditary Angioedema Drug Sales Growth Rate 2015-2020 (K Units)
Figure 97. Middle East and Africa Hereditary Angioedema Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 98. Middle East and Africa Hereditary Angioedema Drug Sales Market Share by Country in 2019
Figure 99. Middle East and Africa Hereditary Angioedema Drug Revenue Market Share by Country in 2019
Figure 100. Turkey Hereditary Angioedema Drug Sales Growth Rate (2015-2020) (K Units)
Figure 101. Turkey Hereditary Angioedema Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 102. Saudi Arabia Hereditary Angioedema Drug Sales Growth Rate (2015-2020) (K Units)
Figure 103. Saudi Arabia Hereditary Angioedema Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. U.A.E Hereditary Angioedema Drug Sales Growth Rate (2015-2020) (K Units)
Figure 105. U.A.E Hereditary Angioedema Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. Middle East and Africa Hereditary Angioedema Drug Market Share by Type in 2019
Figure 107. Middle East and Africa Hereditary Angioedema Drug Market Share by Application in 2019
Figure 108. North America Hereditary Angioedema Drug Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 109. North America Hereditary Angioedema Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 110. Europe Hereditary Angioedema Drug Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 111. Europe Hereditary Angioedema Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 112. Asia Pacific Hereditary Angioedema Drug Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 113. Asia Pacific Hereditary Angioedema Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Latin America Hereditary Angioedema Drug Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 115. Latin America Hereditary Angioedema Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Middle East and Africa Hereditary Angioedema Drug Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 117. Middle East and Africa Hereditary Angioedema Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Porter's Five Forces Analysis
Figure 119. Channels of Distribution
Figure 120. Distributors Profiles
Figure 121. Bottom-up and Top-down Approaches for This Report
Figure 122. Data Triangulation
Figure 123. Key Executives Interviewed
遺伝性血管浮腫の世界市場（～2026年） Hereditary angioedema is a rare disease and is mostly mistaken for common allergic reactions and abdominal pain. This mainly on account of the lack of knowledge among both physicians and patients about the condition. About 40% of the affected patients are diagnosed correctly with hereditary angioede…- レーバー遺伝性視神経症治療薬の世界市場（～2026年） Market Analysis and Insights: Global Leber's Hereditary Optic Neuropathy Drug Market The global Leber's Hereditary Optic Neuropathy Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Leber's Hereditary Optic Neuropat…
- 遺伝性がん検査の世界市場（～2026年） Hereditary cancer testing is a process of identifying an inherited gene mutation that increases the risk of cancer development. It mainly includes predictive genetic testing and clinical DNA sequencing, in predictive genetic testing, patient’s family history is analyzed for any inherited mutation fr…
- 小売薬の世界市場（～2026年） A drug is any substance (other than food that provides nutritional support) that, when inhaled, injected, smoked, consumed, absorbed via a patch on the skin, or dissolved under the tongue causes a temporary physiological (and often psychological) change in the body. Increasing industry share of Asia…
- 血漿プロテアーゼC1阻害剤治療の世界市場（～2026年） This report on the plasma protease C1-inhibitors treatment market analyzes the current and future scenario of the global market. Large number of acute HAE patients is increasing the usage of plasma protease C1-inhibitors treatment. Increasing prevalence of rare diseases around the world, promising p…